MedTrace Logo

Intravenous Immunoglobulins for the Treatment of Covid-19 Patients: a Clinical Trial

NCT04548557 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-09-14

No results posted yet for this study

Summary

The current project is based on the immunological studies covering the potential of disease induced immunoglobulins as treatment regime. We would be able to generate the concentrated antibodies specific against coronavirus (Covid-19). These antibodies can be used as serum therapy. Aside from a Covid-19 vaccine, antibodies from recovered patients could provide a short-term "passive immunization" to the disease. Those antibodies can be extracted from the blood serum of surviving patients and then injected into infected people. Passive immunization usually lasts for a few weeks or months, after which those borrowed or donated antibodies, get broken down by the host body within about 30 days. While drugs to treat patients with covid-19, and vaccines to prevent infection are being developed, a fast acting, stopgap serum therapy could be useful as a first aid for high-risk patients.

Conditions

  • Covid19

Interventions

BIOLOGICAL

intravenous immunoglobulin therapy

It is passive immunization therapy. Plasma therapy is subjected to moderate to severe patients specially, while all effected individuals can take benefit of immunoglobulin therapy because dose of immunoglobulins can be controlled

Sponsors & Collaborators

  • University of Lahore

    collaborator OTHER

  • Amson Vaccine and Pharma (Pvt) Limited

    collaborator INDUSTRY

  • University of Health Sciences Lahore

    lead OTHER

Principal Investigators

  • Javed Akram, MBBS,FRCP,MRCP · Saglik Bilimleri Universitesi

  • Fridoon J Ahmad, Ph.D · Saglik Bilimleri Universitesi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-15
Primary Completion
2020-10-15
Completion
2020-11-15

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04548557 on ClinicalTrials.gov